BPC 157 as Potential Treatment for COVID-19

Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats

“…This vascular failure might be similar to that created with the endothelium-damaging agents’ major intoxication [ 24 , 25 ], myocardial infarction [ 23 ], and maintained severe intra-abdominal hypertension [ 22 ], or those created with major vessel(s) occlusion [ 14 , 15 , 16 , 20 ], veins [ 15 , 16 , 20 ] or arteries [ 14 ], peripheral [ 14 , 15 , 16 ] and central [ 20 ]; however, all were consistently resolved by BPC 157 therapy [ 14 , 15 , 16 , 20 , 23 , 24 , 25 ]. Possibly also in acute pancreatitis and general disturbances (for review, see, i.e., [ 8 , 9 , 10 ]), the BPC 157 bypassing key, as a particular cytoprotection mediator, native and stable in human gastric juice, might bring the upgraded original endothelium/epithelium maintenance background to an observable principle (for review, see i.e., [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]). Evidently, the principle rapidly functions as promptly reestablished and reorganized blood flow (i.e., activated collateral circulation) when the upgraded minor vessel can take over the function of the injured major vessel and overwhelm the Virchow triad circumstances, which is otherwise commonly presented (for review, see i.e., [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]).…”

“…Possibly also in acute pancreatitis and general disturbances (for review, see, i.e., [ 8 , 9 , 10 ]), the BPC 157 bypassing key, as a particular cytoprotection mediator, native and stable in human gastric juice, might bring the upgraded original endothelium/epithelium maintenance background to an observable principle (for review, see i.e., [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]). Evidently, the principle rapidly functions as promptly reestablished and reorganized blood flow (i.e., activated collateral circulation) when the upgraded minor vessel can take over the function of the injured major vessel and overwhelm the Virchow triad circumstances, which is otherwise commonly presented (for review, see i.e., [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]). Illustratively, instead of a completely failed azygos vein (i.e., that commonly noted in “occlusion-like” syndrome studies and Budd-Chiari syndrome [ 13 , 22 , 23 , 24 , 25 ]), there is a prompt and sustained activation of the azygos vein in the BPC 157-treated bile duct-ligated rats.…”

“…Stable gastric pentadecapeptide BPC 157 therapy (for review, see, i.e., [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]) might be important in the full extent of acute pancreatitis and general disturbances (for review, see, i.e., [ 8 , 9 , 10 ]), and might resolve rat acute pancreatitis and occluded bile duct in general vascular failure.…”

“…Of note, all of these disturbances were consistently attenuated with the application of BPC 157 therapy and activation of the collateral pathways, relayed on the given injury [ 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ]. As a particular therapy effect, the BPC 157 regimen was given as intragastric bolus, or continuously orally in drinking water, starting in the early or late advanced injury course (for review, see, i.e., [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]).…”

“…Being stable and native in human gastric juice for more than 24 h, an easy application (i.e., in ulcerative colitis trial, it was safe without adverse effects, and a lethal dose (LD1) was not achieved in toxicology studies) (for review, see i.e., [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ]) may indicate the particular therapy potential of this stable gastric pentadecapeptide BPC 157 in acute pancreatitis. Furthermore, due to its particular vascular recovering potential (for review, see i.e., [ 6 ]), BPC 157 could be fully capable at resolving the complete noxious course, acute pancreatitis, general vascular failure and occlusion-like syndrome.…”